A Study of PHST001 in Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). In Phase 1b cohort expansions, the study will focus on participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma. The study's primary objective is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 monotherapy and in combination with chemotherapy as well as assess the anti-tumor activity of PHST001 and chemotherapy in Phase 1b.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony zaawansowany nowotwór, który nie reaguje na dostępne standardowe leczenie
- •Wystarczająca funkcja narządów wewnętrznych
- •Możliwość zapobiegania ciąży podczas badania
- •Widoczny guz mierzalny w badaniach obrazowych
- •Dobry stan ogólny (skala ECOG 0-1)
✗ Disqualifies
- •Niedostateczna odporność (immunodeficyt)
- •Przebyte inne nowotwory (z wyjątkami jak białaczka skóry lub rak prostaty we wczesnym stadium)
- •Przerzuty do mózgu, które aktywnie się rozwijają lub wymagają sterydów
- •Leczenie innym lekiem przeciwnowotworowym w ciągu ostatnich 3 tygodni
- •Poważne skutki uboczne z poprzedniego leczenia, które nie ustąpiły
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (20)
Precision NextGen Oncology & Research Center
Beverly Hills, United States
USC Norris Comprehensive Cancer Center
Los Angeles, United States
Stanford University School of Medicine
Palo Alto, United States
Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
Denver, United States
Yale Cancer Center
New Haven, United States
University of Chicago Medical Center
Chicago, United States
Dana Farber Cancer Institute
Boston, United States
University of Michigan Rogel Cancer Center
Ann Arbor, United States
START Center for Cancer Research - Midwest
Grand Rapids, United States
START Center for Cancer Research - Long Island New York
Lake Success, United States
Mount Sinai
New York, United States
Duke Cancer Institute
Durham, United States
Sarah Cannon Research Institute (SCRI) Oncology Partners
Nashville, United States
Vanderbilt-Ingram Cancer Center
Nashville, United States
START Center for Cancer Research - Texas
Fort Worth, United States
MD Anderson Cancer Center
Houston, United States
NEXT Oncology - Dallas
Irving, United States
START Center for Cancer Research - San Antonio
San Antonio, United States
University of Texas (UT) Health
San Antonio, United States
NEXT Oncology - Virginia
Fairfax, United States
Trial contact
Andrew Ferguson/VP Clinical Development, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.